A reorganization of manufacturing sites is currently underway in the generic drug industry. With the generic drug share approaching 80% on a volume basis and NHI prices in decline, companies are looking for ways to grow and survive.In July, Nichi-Iko…
BUSINESS
Gilead’s JAK Med Hits Shelves in Japan; Launch Being Prepped for Oral Semaglutide, Rakuten Photoimmunotherapy
After a surprise setback in the US, Gilead Sciences launched its rheumatoid arthritis (RA) drug Jyseleca (filgotinib) in Japan on November 18 upon its reimbursement listing the same day, making it the country’s fifth oral JAK inhibitor for the treatment…
To read the full story
BUSINESS
- Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally
November 20, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Expands Label
November 19, 2020
- Half of Patients Postpone or Cancel Regular Checkups amid COVID-19: Roche Survey
November 19, 2020
- Number of Patients Treated by Pediatricians Shows Sharp Rebound in October: Survey
November 19, 2020
- 20% of Osteoporosis Patients Reduce/Halt Clinic Visits Amid COVID-19 Pandemic: Survey
November 19, 2020
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As I skied the slopes of Hakuba in January, I never would have imagined the world would be in a complete lockdown just a few months later. There’s no question this has been an incredibly challenging year, but there’s good…